Clinilabs, LLC, a contract research organization focused on central nervous system (CNS) drug and medical technology development, has expanded its executive leadership team. David Hagerman has joined as Chief Financial Officer, and Jeanine Falinski has been promoted to Senior Vice President of Commercial Development. These appointments underscore the company's commitment to strengthening its leadership and commercial strategies to support continued growth and innovation in the CNS sector.
David Hagerman brings over 25 years of financial leadership experience in the life sciences and IT industries. His previous roles include CFO at X-Chem and senior financial positions at Charles River Laboratories and Parexel, as well as a 16-year tenure at IBM. Hagerman's expertise is expected to be instrumental in guiding Clinilabs' financial operations and strategic growth initiatives. He will oversee financial planning, risk management, and capital allocation to support the company's expansion.
Jeanine Falinski, who has two decades of pharmaceutical industry experience, rejoined Clinilabs in 2019 after initially starting her career there in 2004. She previously led marketing efforts and has now been promoted to lead the commercial development team. Her role involves enhancing customer engagement and commercial strategies, which are critical for attracting and retaining clients in the competitive CRO market. Falinski's deep understanding of the CNS therapeutic area and her track record in driving business development will be key to Clinilabs' growth.
The strategic appointments come as Clinilabs continues to build on its track record of over 800 CNS clinical trials and contributions to the approval of 23 new therapies across 14 CNS indications. The company specializes in psychiatric, neurological, and substance use disorders, as well as rare CNS diseases. By bolstering its executive team, Clinilabs aims to maintain its position as a leader in CNS drug development, offering high-quality and efficient clinical development services to global clients.
These leadership changes signal a focus on financial stability and commercial expansion, which are essential for navigating the complexities of drug development. As the CNS therapeutic area faces high failure rates and regulatory challenges, Clinilabs' strengthened leadership may improve its ability to deliver innovative solutions and support its clients in bringing new treatments to market. The appointments reflect a broader trend in the CRO industry where companies are investing in executive talent to drive differentiation and growth.
